TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.
Jiangsu Recbio Technology Co., Ltd. announced the acceptance of its application for a clinical trial of its new HPV 9-valent vaccine, REC604c, by the National Medical Products Administration in China. The REC604c vaccine, enhanced with a novel adjuvant developed in-house, seeks to reduce vaccination doses while boosting immunogenicity and cross-protection. This development targets the male market, acknowledging the global trend of including adolescent males in HPV vaccination programs. The potential market in China is significant, with over 300 million eligible males, but success is not guaranteed.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative vaccines. The company specializes in recombinant vaccines, targeting markets for various age groups and genders.
YTD Price Performance: -8.63%
Average Trading Volume: 31,379
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$3.96B
Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.